Share Name Share Symbol Market Type Share ISIN Share Description
Smith & Nephew Plc LSE:SN. London Ordinary Share GB0009223206 ORD USD0.20
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 1,684.50 844,874 14:31:14
Bid Price Offer Price High Price Low Price Open Price
1,684.00 1,684.50 1,702.00 1,682.00 1,686.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 3,845.52 612.43 59.60 29.1 14,735
Last Trade Time Trade Type Trade Size Trade Price Currency
14:31:14 AT 217 1,684.50 GBX

Smith & Nephew (SN.) Latest News

More Smith & Nephew News
Smith & Nephew Takeover Rumours

Smith & Nephew (SN.) Discussions and Chat

Smith & Nephew Forums and Chat

Date Time Title Posts
21/10/201922:51*** Smith and Nephew ***299
29/10/201508:48SN.122
10/1/201113:03Smith and Nephew 200867
09/1/201117:12Smiths: Charts and News etc.296
25/9/200614:09Smith&Nep. Why the rise?75

Add a New Thread

Smith & Nephew (SN.) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
14:31:141,684.502173,655.37AT
14:31:141,684.5023387.44AT
14:31:101,685.002293,858.65AT
14:31:101,685.002173,656.45AT
14:31:101,685.0071712,081.45AT
View all Smith & Nephew trades in real-time

Smith & Nephew (SN.) Top Chat Posts

DateSubject
11/12/2019
08:20
Smith & Nephew Daily Update: Smith & Nephew Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker SN.. The last closing price for Smith & Nephew was 1,684.50p.
Smith & Nephew Plc has a 4 week average price of 1,629p and a 12 week average price of 1,614p.
The 1 year high share price is 1,998p while the 1 year low share price is currently 1,383p.
There are currently 874,737,317 shares in issue and the average daily traded volume is 1,694,466 shares. The market capitalisation of Smith & Nephew Plc is £14,726,202,731.70.
21/10/2019
20:50
kknight01: The company is certainly strong and I think what Namal brought was some guts to go out and start buying up small med tech companies to bolster the portfolio which if definitely the right way to go. I do hope his successor continues the momentum, sales are not going to diminish due to his departure, I think it is safe to day that medical device manufacturers are a good buy, with people living longer and the demand on healthcare increasing. The majority of the share price valuation was based on Namal's attitude to business and believe it will recover in time. In my opinion, we have an excellent t buying opportunity ahead and like you said, could very well be snapped up by a bigger fish any time.
21/10/2019
08:55
steeplejack: Smith & Nephew"Can anything stop the exodus of FTSE 100 chief executives in 2019? The numbers have now been bolstered to the point where these departing CEOs could almost cobble together an 11-a-side football match as Smith & Nephew's Namal Nawana steps down."Australian Nawana has only been in post for 18 months but has already helped revive the share price with a new strategy."This culminated in re-organising the business into three global franchises: orthopaedics, sports medicine and advanced wound management."The market responded positively to this simplified structure, which reduced duplication of effort and made reporting responsibilities clearer with better accountability."There appears to be a pretty simple reason Nawana is leaving – pay. It became apparent over the summer that the company was looking for ways to increase its head honcho's remuneration with apparent discussions about a move to a US listing to escape an increasing backlash in the UK towards excessive executive pay."The fear will be that this revamp of the business will be derailed by Nawana's departure despite efforts to allay these concerns – with internal candidate Roland Diggelmann stepping up to the top job and Nawana staying to smooth the transition until the end of the year."Diggelmann faces a tricky task of balancing the need for continuity with a likely ambition to bring his own ideas to the role."
19/8/2019
20:08
adamb1978: How much of the share price performance is simply FX driven? They report in $ and I suspect price in $ meaning having the £ head to the low 1.20s vs the $ helps them materially - its all extra revenue with no cost against it so falls straight through to the bottom line
11/2/2019
12:20
steeplejack: Smith & Nephew was the biggest faller on the FTSE 100 this morning with shares down more than four per cent on reports it is in talks to buy US spine technology Nuvasive in a $3bn (£2.32bn) deal. Shares fell 4.39 per cent to 1,448p today, having closed on Friday at 1,515p. The Financial Times reported the potential deal on Friday after markets closed, sending Nuvasive’s share price up 25 per cent in after hours trading.
08/2/2019
04:45
kknight01: I would say hold and watch this space. Olivier was a waste of space. Namal has brought in a strong leadership with particular emphasis on commercial and operations. Exciting times ahead for this great British company and if it does go wrong I would expect take over bid rumours for some on its franchises which will only push up the share price some more. Buy back when share price dips again!
03/5/2018
07:17
steeplejack: The guidance has been trimmed from revenue growth of 3-4% at the time of the finals to 2-3% now.The suggestion is that things will stabilise and return to a more normal pattern in the rest of the year.Emerging markets are encouraging.Whether this update is worth over 7% off the share price is questionable especially given the corporate activity just now in the sector.Yet the shares have been very strong of late and are vulnerable to top slicing.Maybe I'm too simplistic but I never really worry about my holding in Smith & Nephew.I always feel that if things take an enduring turn for the worse,someone will take the company over.
19/1/2018
08:39
basil brush1: imo lots of support at 1230. the big question is will there be a bid before the new CEO is appointed? looks vulnerable as share price has not changed in dollar terms in nearly 4 years. Stryker has doubled in the same period.
26/11/2016
09:06
accipitridae: Get hip to Smith & Nephew's investment appeal, Goldman advises Share 10:36 25 Nov 2016 The hip and joint replacement specialist trades at a discount to sector peer Stryker Goldman Sachs has lowered its earnings estimates for Smith & Nephew PLC (LON:SN. but still rates the medical technology company’s shares a ‘buy’. The estimate changes follow the third quarter trading update earlier this morning and recent exchange rate movements, and see this year’s earnings per share (EPS) forecast decline 3%, while EPS estimates for the next three years have been shaved by 8%, reflecting weaker growth patterns in the third quarter. “While organic revenue growth this year has fallen short of our expectations (we now expect Smith & Nephew to deliver 1.9% organic revenue growth in 2016, down from the 5% that we had forecast at the beginning of 2016, with the slowdown driven largely by China and the Middle East), we continue to believe that SN.L will accelerate organic revenue growth into the 4%-5% range in 2017 and beyond, given its geographic and product mix (>50% of revenues is in higher-growth markets) and a number of upcoming product launches (Renasys Touch and Connect, Navio in total knee, revision hip, and WereWolf),” the heavyweight US investment bank said. The next catalyst for the share price is likely to be the appointment of a chief financial officer, expected before the end of the year. Goldman’s lowered its price target to 1,310p from 1,370p, on the assumption that Smith & Nephew will trade around 18 times projected EPS for 2018; it currently trades at 15.4 times 2018 EPS, whereas sector peer Stryker Corporation (NYSE:SYK) trades on an earnings multiple of 17.4, despite a comparable growth outlook. Goldman deems the disparity as unwarranted, and in fact suggests S&N should trade at a premium to Stryker, thanks to the possibility of being taken out by a competitor.
10/8/2016
11:12
mikeindevon: Whichever way you look at it that 300m, 25p per share is 'lost' to the company ... it's not being used to grow the business, it's not being used to invest in new plant or projects it's being spent in an incestuous deal to buy back its own shares. Apart from a small, temporary fillip to the share price ... and yesterdays buy of £4m worth of shares produced zero addition of value ... it does nothing for us small shareholders. Rather it deprives us of 2% of yield. But it does increase the EPS by about the same amount ... by cancelling shares. So who does that benefit? It only benefits folk who hold few or no shares but gain from an increase in EPS ... and that smacks of bonus related management payments to me. As I say, call me a cynic ... but that's why I say buy backs are bad news to shareholders ... of course if I was particularly jaundiced I'd be thinking that maybe the brokers have a specific buyer that they buy the shares from ... but that would be a very different game and completely contrary to the free and open market principle. Mike
01/4/2014
21:15
knighty0001: President of AWM Roger Teasdale is leaving the business at the end of the month. Has this been announced externally yet? Not sure what impact to share price this could have? If any at all.
Smith & Nephew share price data is direct from the London Stock Exchange
Your Recent History
LSE
SN.
Smith & Ne..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191211 14:46:17